Seeking Alpha

ImmunoCellular cut in half as ICT-107 misses primary OS endpoint

  • ImmunoCellular (IMUC) collapses 50% AH.
  • The company is out with results from a Phase 2 study of ICT-107 in newly diagnosed glioblastoma multiforme.
  • ICT-107 showed statistically significant PFS superiority over placebo. K-M curves (entire sample of 124 patients): Favors ICT-107; HR of 0.56; p=0.014; median PFS increase was two months. K-M curves (per-protocol population): Favors ICT-107; HR of 0.53; p=0.0074; median PFS increase was three months.
  • OS K-M curves fail to hit statistical significance. OS was the primary endpoint. Summary (intent-to-treat): HR of 0.87; p=0.58. Summary (per-protocol): HR of 0.79; p=0.40.
  • For more, see here.
Comments (6)
  • BrennanNoall
    , contributor
    Comments (79) | Send Message
     
    Another one bites the dust - and another one gone and another one gone - this is getting way too expensive!
    11 Dec 2013, 08:08 PM Reply Like
  • dblack0022
    , contributor
    Comments (11) | Send Message
     
    Still positive data....
    11 Dec 2013, 08:43 PM Reply Like
  • dblack0022
    , contributor
    Comments (11) | Send Message
     
    Still positive data....
    11 Dec 2013, 08:43 PM Reply Like
  • hs070169
    , contributor
    Comments (2) | Send Message
     
    seems like a buying opportunity. If I had GBM, this is a ray of hope
    11 Dec 2013, 10:14 PM Reply Like
  • Pgman701
    , contributor
    Comments (102) | Send Message
     
    Nope this a goner!!
    12 Dec 2013, 06:53 AM Reply Like
  • Market DJ
    , contributor
    Comments (698) | Send Message
     
    Still positive data? Wow? Good luck, investing?......
    12 Dec 2013, 08:32 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs